OncoSec Medical, Inc. (OTCQB: ONCS) is a biopharmaceutical company focused on developing its advanced-stage ImmunoPulse DNA-based immunotherapy therapy to treat solid tumor cancers. The company’s treatment aims to harness the body’s immune system to target and kill cancer cells and consists of using its proprietary electroporation platform to enhance the uptake of a locally delivered DNA-based immunocytokine. OncoSec’s broader mission is to pioneer and refine new electroporation technologies that strive to benefit patients and enhance the quality of life for those whose skin cancers cannot be treated effectively with conventional treatment approaches. For more information, visit the company’s website at www.oncosec.com